Covid-19 Research

Review Article

A Systematic Review of Intravenous Psychoactive Drug Use among Adolescent Females

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Review Article
Subject Medicine Group
OCLC JBRES Record
Nkporbu AK*, Metu I and Stanley PC
Issue: Volume4-Issue3
Pages: 321-330
Received: 2023-02-01
Accepted: 2023-03-02
Published: 2023-03-07

Abstract

Background: In the twenty-first century, female adolescents’ use of intravenous psychoactive substances has become widespread worldwide. For instance, statistics show that 155 and 250 million people between the ages of 15-64 used intravenous psychoactive drugs as of 2008. Examples of intravenous psychoactive drugs taken by people with 15-64 include; Amphetamines, non-prescribed psychoactive prescription drugs, cannabis, cocaine, and opiates. As a result of the preceding, the use of intravenous psychoactive drugs among Female adolescents is a common phenomenon in the 21st century.

Aim: To undergo a systematic review on IV psychoactive drugs use, prevalence, causes and effects among adolescent females.

Design: A systematic review.

Data Sources: Systematic search for worldwide published literature from databases like google scholar, Emerald, PubMed, and science-direct.
Study Eligibility Criteria: Articles that are published in English, primary research and studies published within the last 10 (ten) years (2013-2023).

Results: From the 2000 published papers that was found, 1700 publications were screened out owing to duplicate data. In addition, 60 publications were eliminated because they did not have appropriate information for this current study, and 200 papers were eliminated because of erroneous information. For being overly shallow, 29 publications were ignored. In the end, this study included 11 (eleven) publications.

Conclusion: Worldwide, there is a high prevalence of female adolescents using intravenous psychoactive drugs. The causes include feelings of helplessness following family separation, poor academic performance, a physical environment, prior substance use, recreational alternatives, socialisation issues, and inadequate organisational support. Cardiovascular illness, psychological diseases like anxiety, dependency, mood, and psychosis disorders, as well as various Hormonal Contraceptives, are all consequences of intravenous psychoactive drug use among female teenagers (HC). According to this study, more Motivational Enhancement Therapy (MET), family counselling, and cognitive-behavioural therapy should be used to free female adolescents from the shackles of intravenous psychoactive substance use.

FullText HTML FullText PDF DOI: 10.37871/jbres1679 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2023 Nkporbu AK, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Nkporbu AK, Metu I, Stanley PC. A Systematic Review of Intravenous Psychoactive Drug Use among Adolescent Females. 2023 Mar 07; 4(3): 321-330. doi: 10.37871/jbres1679, Article ID: JBRES1679, Available at: https://www.jelsciences.com/ articles/jbres1679.pdf

Subject area(s)

Pharmacology

References

  1. Müller CP. Drug instrumentalization. Behav Brain Res. 2020 Jul 15;390:112672. doi: 10.1016/j.bbr.2020.112672. Epub 2020 May 19. PMID: 32442549.
  2. Moncrieff J. Research on a 'drug-centred' approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs. Epidemiol Psychiatr Sci. 2018 Apr;27(2):133-140. doi: 10.1017/S2045796017000555. Epub 2017 Oct 12. PMID: 29022518; PMCID: PMC6998955.
  3. Sanz C, Zamberlan F, Erowid E, Erowid F, Tagliazucchi E. The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports. Front Neurosci. 2018 Jan 22;12:7. doi: 10.3389/fnins.2018.00007. Erratum in: Front Neurosci. 2018 Apr 11;12 :229. PMID: 29403350; PMCID: PMC5786560.
  4. Frone MR. Employee psychoactive substance involvement: Historical context, key findings, and future directions. Annual Review of Organizational Psychology and Organizational Behaviour. 2019;6(1):273-297. doi: 10.1146/annurev-orgpsych-012218-015231.
  5. Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, White J, Thomas KV, Farrell M, Griffiths P. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019 Nov 2;394(10209):1668-1684. doi: 10.1016/S0140-6736(19)32231-7. Epub 2019 Oct 23. PMID: 31668410.
  6. Quinlan J, Cox F. Acute pain management in patients with drug dependence syndrome. Pain Rep. 2017 Jul 27;2(4):e611. doi: 10.1097/PR9.0000000000000611. PMID: 29392226; PMCID: PMC5741366.
  7. Plumber N, Majeed M, Ziff S, Thomas SE, Bolla SR, Gorantla VR. Stimulant Usage by Medical Students for Cognitive Enhancement: A Systematic Review. Cureus. 2021 May 22;13(5):e15163. doi: 10.7759/cureus.15163. PMID: 34178492; PMCID: PMC8216643.
  8. Loganathan K, Lv J, Cropley V, Zalesky A, Ho ETW. Valuation system connectivity is correlated with poly-drug use in young adults. Neurosci Res. 2021 Dec;173:114-120. doi: 10.1016/j.neures.2021.06.006. Epub 2021 Jun 29. PMID: 34214618.
  9. Bouso JC, Ona G, Kohek M, Dos Santos RG, Hallak JEC, Alcázar-Córcoles MÁ, Obiols-Llandrich J. Hallucinations and Hallucinogens: Psychopathology or Wisdom? Cult Med Psychiatry. 2023 Jan 12:1–29. doi: 10.1007/s11013-022-09814-0. Epub ahead of print. PMID: 36633720; PMCID: PMC9838303.
  10. Visconti AJ, Sell J, Greenblatt AD. Primary Care for Persons Who Inject Drugs. Am Fam Physician. 2019 Jan 15;99(2):109-116. PMID: 30633481.
  11. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7. PMID: 30001569; PMCID: PMC6177698.
  12. Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018 Feb 15;195:44-52. doi: 10.1016/j.lfs.2017.12.025. Epub 2017 Dec 22. PMID: 29277310.
  13. Simmons RG, Blyth DA. Moving into Adolescence. Simmons RG, editor. Routledge; 2017.
  14. Muhammad T, Srivastava S, Kumar P, Patel SK. What predicts the early sexual debut among unmarried adolescents (10-19 years)? Evidence from UDAYA survey, 2015-16. PLoS One. 2021 Jun 10;16(6):e0252940. doi: 10.1371/journal.pone.0252940. PMID: 34111205; PMCID: PMC8192016.
  15. Clark H, Coll-Seck AM, Banerjee A, Peterson S, Dalglish SL, Ameratunga S, Balabanova D, Bhan MK, Bhutta ZA, Borrazzo J, Claeson M, Doherty T, El-Jardali F, George AS, Gichaga A, Gram L, Hipgrave DB, Kwamie A, Meng Q, Mercer R, Narain S, Nsungwa-Sabiiti J, Olumide AO, Osrin D, Powell-Jackson T, Rasanathan K, Rasul I, Reid P, Requejo J, Rohde SS, Rollins N, Romedenne M, Singh Sachdev H, Saleh R, Shawar YR, Shiffman J, Simon J, Sly PD, Stenberg K, Tomlinson M, Ved RR, Costello A. A future for the world's children? A WHO-UNICEF-Lancet Commission. Lancet. 2020 Feb 22;395(10224):605-658. doi: 10.1016/S0140-6736(19)32540-1. Epub 2020 Feb 19. Erratum in: Lancet. 2020 May 23;395(10237):1612. PMID: 32085821.
  16. Pérez-Mañá C, Papaseit E, Fonseca F, Farré A, Torrens M, Farré M. Drug Interactions With New Synthetic Opioids. Front Pharmacol. 2018 Oct 11;9:1145. doi: 10.3389/fphar.2018.01145. PMID: 30364252; PMCID: PMC6193107.
  17. Ibrahim Y, Hussain SM, Alnasser S, Almohandes H, Sarhandi I. Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. Ann Saudi Med. 2018 Sep-Oct;38(5):319-325. doi: 10.5144/0256-4947.2018.319. PMID: 30284986; PMCID: PMC6180213.
  18. Ritchie H, Roser M. Alcohol consumption. Our World in Data. 2018.
  19. Cunningham JA, Godinho A, Kushnir V. Can Amazon's Mechanical Turk be used to recruit participants for internet intervention trials? A pilot study involving a randomized controlled trial of a brief online intervention for hazardous alcohol use. Internet Interv. 2017 Sep 9;10:12-16. doi: 10.1016/j.invent.2017.08.005. PMID: 30135748; PMCID: PMC6084901
  20. Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham EB, Dumchev K, Lynskey M, Stone J, Trickey A, Razavi H, Mattick RP, Farrell M, Dore GJ, Degenhardt L. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019 Jan;114(1):150-166. doi: 10.1111/add.14393. Epub 2018 Aug 28. PMID: 30035835; PMCID: PMC6657799.
  21. Massey SH, Newmark RL, Wakschlag LS. Explicating the role of empathic processes in substance use disorders: A conceptual framework and research agenda. Drug Alcohol Rev. 2018 Mar;37(3):316-332. doi: 10.1111/dar.12548. Epub 2017 May 10. PMID: 28493364; PMCID: PMC5681447.
  22. Janicijevic KM, Kocic SS, Radevic SR, Jovanovic MR, Radovanovic SM. Socioeconomic Factors Associated with Psychoactive Substance Abuse by Adolescents in Serbia. Front Pharmacol. 2017 Jun 13;8:366. doi: 10.3389/fphar.2017.00366. PMID: 28659800; PMCID: PMC5468426.
  23. Wickham SR, Amarasekara NA, Bartonicek A, Conner TS. The Big Three Health Behaviors and Mental Health and Well-Being Among Young Adults: A Cross-Sectional Investigation of Sleep, Exercise, and Diet. Front Psychol. 2020 Dec 10;11:579205. doi: 10.3389/fpsyg.2020.579205. PMID: 33362643; PMCID: PMC7758199.
  24. Fattore L, Marti M, Mostallino R, Castelli MP. Sex and Gender Differences in the Effects of Novel Psychoactive Substances. Brain Sci. 2020 Sep 3;10(9):606. doi: 10.3390/brainsci10090606. PMID: 32899299; PMCID: PMC7564810.
  25. Tanner-Smith E, Steinka-Fry K, Kettrey H, Lipsey M. Adolescent substance use treatment effectiveness: A systematic review and meta-analysis. 2016.
  26. Cairns R, Karanges EA, Wong A, Brown JA, Robinson J, Pearson SA, Dawson AH, Buckley NA. Trends in self-poisoning and psychotropic drug use in people aged 5-19 years: a population-based retrospective cohort study in Australia. BMJ Open. 2019 Feb 20;9(2):e026001. doi: 10.1136/bmjopen-2018-026001. PMID: 30787095; PMCID: PMC6398641.
  27. Lopes GM, Nóbrega BA, Del Prette G, Scivoletto S. Use of psychoactive substances by adolescents: current panorama. Braz J Psychiatry. 2013;35 Suppl 1:S51-61. doi: 10.1590/1516-4446-2013-S105. PMID: 24142128.
  28. Tomczyk S, Isensee B, Hanewinkel R. Latent classes of polysubstance use among adolescents-a systematic review. Drug Alcohol Depend. 2016 Mar 1;160:12-29. doi: 10.1016/j.drugalcdep.2015.11.035. Epub 2015 Dec 11. PMID: 26794683.
  29. Ho BC, Barry AB, Koeppel JA, Macleod J, Boyd A, David A, O’Leary DS. Recreational marijuana use, adolescent cognitive development and schizophrenia susceptibility. Biological Psychiatry Global Open Science. 2022. doi: 10.1016/j.bpsgos.2022.01.008.
  30. Luthar SS, Small PJ, Ciciolla L. Adolescents from upper middle class communities: Substance misuse and addiction across early adulthood. Dev Psychopathol. 2018 Feb;30(1):315-335. doi: 10.1017/S0954579417000645. Epub 2017 May 31. Erratum in: Dev Psychopathol. 2018 May;30(2):715-716. PMID: 28558858.
  31. Moore K, Wells H, Feilding A. Roadmaps to regulation: MDMA. Beckley foundation. 2019.
  32. Embleton L, Mwangi A, Vreeman R, Ayuku D, Braitstein P. The epidemiology of substance use among street children in resource-constrained settings: a systematic review and meta-analysis. Addiction. 2013 Oct;108(10):1722-33. doi: 10.1111/add.12252. Epub 2013 Jul 12. PMID: 23844822; PMCID: PMC3776018.
  33. Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, Chillemi E, Bonifaci L, Janiri L, Di Giannantonio M. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol. 2015 Jul;30(4):295-301. doi: 10.1002/hup.2486. PMID: 26216566.
  34. Tomaszek K, Muchacka-Cymerman A. Sex Differences in the Relationship between Student School Burnout and Problematic Internet Use among Adolescents. Int J Environ Res Public Health. 2019 Oct 24;16(21):4107. doi: 10.3390/ijerph16214107. PMID: 31653105; PMCID: PMC6862502.
  35. Anetor GA. The socio-economic effects of substance abuse in Nigerian youths: A case study of neuro-psychiatric hospital, yaba, lagos. Archives of Basic and Applied Medicine. 2019;7(1): 4641-4646.
  36. Okogbenin E. Psychoactive substance use among adolescents in Nigeria: A systematic review. International Journal of Science Academic Research. 2021.
  37. Sitaram SK. Pattern of substance abuse among children in slum areas of India. Substance use disorder: New research perspectives in the diagnosis. Treatment, and Prognosis. 2022. doi: 10.5772/intechopen.105596.
  38. Bhandari TR, Khatiwada B, Rajbhandari B, Bestman A, Mistry SK, Rayamajhee B, Rawal LB, Yadav UN. A qualitative study to understand drivers of psychoactive substance use among Nepalese youth. PLoS One. 2021 Nov 5;16(11):e0259021. doi: 10.1371/journal.pone.0259021. PMID: 34739508; PMCID: PMC8570474.
  39. Shek DTL, Zhu X, Dou D, Chai W. Influence of Family Factors on Substance Use in Early Adolescents: A Longitudinal Study in Hong Kong. J Psychoactive Drugs. 2020 Jan-Mar;52(1):66-76. doi: 10.1080/02791072.2019.1707333. Epub 2019 Dec 22. PMID: 31865866.
  40. Shek DTL, Zhu X, Ma CMS. The Influence of Parental Control and Parent-Child Relational Qualities on Adolescent Internet Addiction: A 3-Year Longitudinal Study in Hong Kong. Front Psychol. 2018 May 1;9:642. doi: 10.3389/fpsyg.2018.00642. PMID: 29765349; PMCID: PMC5938405.
  41. Kahsay ZH, Tesema AG, Bazzano AN. A qualitative study of drivers of psychoactive substance use among Mekelle University students, Northern Ethiopia. Subst Abuse Treat Prev Policy. 2019 Mar 4;14(1):11. doi: 10.1186/s13011-018-0190-1. PMID: 30832696; PMCID: PMC6398241.
  42. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J Psychiatry Neurosci. 2016 Mar;41(2):89-104. doi: 10.1503/jpn.140217. PMID: 26447819; PMCID: PMC4764485.
  43. Brouillette J, Nattel S. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. Can J Cardiol. 2017 Dec;33(12):1577-1586. doi: 10.1016/j.cjca.2017.09.001. Epub 2017 Sep 11. PMID: 29173600.
  44. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018 Mar-Apr;59(2):105-122. doi: 10.1016/j.psym.2017.10.009. Epub 2017 Nov 3. PMID: 29275963.
  45. Ray V, Waite MR, Spexarth FC, Korman S, Berget S, Kodali S, Kress D, Guenther N, Murthy VS. Addiction Management in Hospitalized Patients With Intravenous Drug Use-Associated Infective Endocarditis. Psychosomatics. 2020 Nov-Dec;61(6):678-687. doi: 10.1016/j.psym.2020.06.019. Epub 2020 Jul 2. PMID: 32778422.
  46. Lucatch AM, Lowe DJE, Clark RC, Kozak K, George TP. Neurobiological Determinants of Tobacco Smoking in Schizophrenia. Front Psychiatry. 2018 Dec 6;9:672. doi: 10.3389/fpsyt.2018.00672. PMID: 30574101; PMCID: PMC6291492.
  47. Kapitány-Fövény M, Farkas J, Pataki PA, Kiss A, Horváth J, Urbán R, Demetrovics Z. Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms. Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2602. Epub 2017 Jun 15. PMID: 28618002.
  48. Parker C, Tejerina-Arreal M, Henley W, Goodman R, Logan S, Ford T. Are children with unrecognised psychiatric disorders being excluded from school? A secondary analysis of the British Child and Adolescent Mental Health Surveys 2004 and 2007. Psychol Med. 2019 Nov;49(15):2561-2572. doi: 10.1017/S0033291718003513. Epub 2018 Dec 20. PMID: 30572975.
  49. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018 Mar 22;13(3):e0194773. doi: 10.1371/journal.pone.0194773. PMID: 29566064; PMCID: PMC5864056.
  50. Rehm J, Probst C, Falcón LL, Shield KD. Burden of disease: The epidemiological aspects of addiction. Textbook of Addiction Treatment. 2020;51-64. doi: 10.1007/978-88-470-5322-9.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership